Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection.
暂无分享,去创建一个
Chuan Qin | Jie Peng | Qiang Wei | Kwok-Hung Chan | Xavier Alvarez | Kwok-Hung Chan | Zhiwei Chen | K. Yuen | S. Perlman | A. Lackner | C. Qin | Kwok-Yung Yuen | Andrew Lackner | Stanley Perlman | Li Liu | Qingqing Lin | Jun Fang | Haibo Wang | Hauyee Kwok | Hangying Tang | Kenji Nishiura | Zhiwu Tan | Tongjin Wu | Ka-Wai Cheung | Zhiwei Chen | Q. Lin | Q. Wei | Z. Tan | Li Liu | Ka-wai Cheung | X. Alvarez | Jie Peng | K. Nishiura | Haibo Wang | Jun Fang | Hangying Tang | H. Kwok | Tongjin Wu
[1] R. Couch,et al. Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus , 2012, PloS one.
[2] Jincun Zhao,et al. Virus-Specific Memory CD8 T Cells Provide Substantial Protection from Lethal Severe Acute Respiratory Syndrome Coronavirus Infection , 2014, Journal of Virology.
[3] Y. Zhang,et al. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine , 2005, Vaccine.
[4] T. Wynn,et al. Macrophages in Tissue Repair, Regeneration, and Fibrosis. , 2016, Immunity.
[5] S. Morikawa,et al. Effects of Toll-Like Receptor Stimulation on Eosinophilic Infiltration in Lungs of BALB/c Mice Immunized with UV-Inactivated Severe Acute Respiratory Syndrome-Related Coronavirus Vaccine , 2014, Journal of Virology.
[6] K. To,et al. High Titer and Avidity of Nonneutralizing Antibodies against Influenza Vaccine Antigen Are Associated with Severe Influenza , 2012, Clinical and Vaccine Immunology.
[7] J. Sung,et al. Retrospective comparison of convalescent plasma with continuing high‐dose methylprednisolone treatment in SARS patients , 2004, Clinical Microbiology and Infection.
[8] J. Edwards,et al. Exploring the full spectrum of macrophage activation , 2008, Nature Reviews Immunology.
[9] J. Tregoning,et al. Immune Responses and Disease Enhancement during Respiratory Syncytial Virus Infection , 2005, Clinical Microbiology Reviews.
[10] Y. Guan,et al. Confronting SARS: a view from Hong Kong. , 2004, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[11] N. Petrovsky,et al. Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology , 2014, Journal of Virology.
[12] M. Kuroda,et al. In Vivo Characterization of Alveolar and Interstitial Lung Macrophages in Rhesus Macaques: Implications for Understanding Lung Disease in Humans , 2014, The Journal of Immunology.
[13] S. Goerdt,et al. Macrophage activation and polarization: nomenclature and experimental guidelines. , 2014, Immunity.
[14] Taeg S. Kim,et al. Regulating the adaptive immune response to respiratory virus infection , 2012, Nature Reviews Immunology.
[15] A. Lackner,et al. Recently infiltrating MAC387(+) monocytes/macrophages a third macrophage population involved in SIV and HIV encephalitic lesion formation. , 2011, The American journal of pathology.
[16] L. Wen,et al. Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys , 2005, Vaccine.
[17] Jing Xie,et al. Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates , 2016, ACS infectious diseases.
[18] W. Marasco,et al. An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus , 2005, The Journal of pathology.
[19] T. Wynn,et al. Protective and pathogenic functions of macrophage subsets , 2011, Nature Reviews Immunology.
[20] K. Yuen,et al. Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-CoV Infection1 , 2008, The Journal of Immunology.
[21] F. Polack,et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes , 2010, Nature Medicine.
[22] S. Perlman,et al. Complete Protection against Severe Acute Respiratory Syndrome Coronavirus-Mediated Lethal Respiratory Disease in Aged Mice by Immunization with a Mouse-Adapted Virus Lacking E Protein , 2013, Journal of Virology.
[23] W. Lim,et al. The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis , 2014, The Journal of infectious diseases.
[24] K. Yuen,et al. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection , 2008, Vaccine.
[25] Yan Guo,et al. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model , 2006, Vaccine.
[26] Lisa E. Gralinski,et al. A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge , 2011, Journal of Virology.
[27] M. Matthay,et al. The acute respiratory distress syndrome. , 1996, The New England journal of medicine.
[28] N. Zhong,et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque , 2005, Nature Medicine.
[29] L. Poon,et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study , 2003 .
[30] Christian Drosten,et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.
[31] M. Peiris,et al. SARS: clinical virology and pathogenesis , 2003, Respirology.
[32] D. Ho,et al. Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals , 2005, Journal of medical virology.
[33] Jincun Zhao,et al. T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice , 2010, Journal of Virology.
[34] M. Neurath,et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.
[35] M. Schilham,et al. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ , 2014, Journal of experimental & clinical cancer research : CR.
[36] U. Parashar,et al. Severe Acute Respiratory Syndrome in Children , 2007, The Pediatric infectious disease journal.
[37] S. Asa,et al. Pulmonary pathology of severe acute respiratory syndrome in Toronto , 2005, Modern Pathology.
[38] K. Mayer,et al. Acute Lung Injury: How Macrophages Orchestrate Resolution of Inflammation and Tissue Repair , 2011, Front. Immun..
[39] J. A. Comer,et al. A novel coronavirus associated with severe acute respiratory syndrome. , 2003, The New England journal of medicine.
[40] R. Baric,et al. Airway Memory CD4+ T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses , 2016, Immunity.
[41] David K. Meyerholz,et al. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice , 2016, Cell Host & Microbe.
[42] D. Ho,et al. Recombinant Modified Vaccinia Virus Ankara Expressing the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus Induces Protective Neutralizing Antibodies Primarily Targeting the Receptor Binding Region , 2005, Journal of Virology.
[43] P. Chan,et al. Use of convalescent plasma therapy in SARS patients in Hong Kong , 2004, European Journal of Clinical Microbiology and Infectious Diseases.
[44] Zhiwei Chen,et al. Monoclonal antibodies specific to human Δ42PD1: A novel immunoregulator potentially involved in HIV-1 and tumor pathogenesis , 2015, mAbs.
[45] Arthur S Slutsky,et al. Identification of Oxidative Stress and Toll-like Receptor 4 Signaling as a Key Pathway of Acute Lung Injury , 2008, Cell.
[46] K. Harrod,et al. Primary Severe Acute Respiratory Syndrome Coronavirus Infection Limits Replication but Not Lung Inflammation upon Homologous Rechallenge , 2012, Journal of Virology.
[47] S. Perlman,et al. Immunopathogenesis of coronavirus infections: implications for SARS , 2005, Nature Reviews Immunology.
[48] D. Ho,et al. Single Amino Acid Substitutions in the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Determine Viral Entry and Immunogenicity of a Major Neutralizing Domain , 2005, Journal of Virology.
[49] Zhiwei Chen,et al. Spatiotemporal interplay of severe acute respiratory syndrome coronavirus and respiratory mucosal cells drives viral dissemination in rhesus macaques , 2015, Mucosal Immunology.
[50] M. Barry,et al. The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[51] Gary J. Nabel,et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice , 2004, Nature.
[52] Michelle M. Packard,et al. Prior Infection and Passive Transfer of Neutralizing Antibody Prevent Replication of Severe Acute Respiratory Syndrome Coronavirus in the Respiratory Tract of Mice , 2004, Journal of Virology.